N-tert-butoxycarbonyl-piperazinethanoic acid hydrochloride | 362690-45-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-tert-butoxycarbonyl-piperazinethanoic acid hydrochloride
• 英文别名: N-Boc-piperazinethanoic acid hydrochloride；2-(4-(tert-Butoxycarbonyl)piperazin-1-yl)acetic acid hydrochloride；2-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]acetic acid;hydrochloride
• CAS: 362690-45-7
• 化学式: C₁₁H₂₀N₂O₄*ClH
• mdl: MFCD02093550
• 分子量: 280.752
• InChiKey: FTUAXOIRCMDORP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.48
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.818
• 拓扑面积：
  70.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-tert-butoxycarbonyl-piperazinethanoic acid hydrochloride 在 盐酸 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.5h， 生成
  参考文献：
  名称：

  [EN] GLUTARIMIDE COMPOUND AND USE THEREOF
  [FR] COMPOSÉ DE GLUTARIMIDE ET SON UTILISATION
  [ZH] 戊二酰亚胺类化合物与其应用

  摘要：

  本发明公开了一种戊二酰亚胺类化合物与其应用。具体公开了式(VII-0)所示化合物及其药学上可接受的盐。

  公开号：

  WO2023036175A1
• 作为产物：
  描述：

  N-Boc-哌嗪 在 lithium hydroxide monohydrate 、 水 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 5.0h， 生成 N-tert-butoxycarbonyl-piperazinethanoic acid hydrochloride
  参考文献：
  名称：

  [EN] GLUTARIMIDE COMPOUND AND USE THEREOF
  [FR] COMPOSÉ DE GLUTARIMIDE ET SON UTILISATION
  [ZH] 戊二酰亚胺类化合物与其应用

  摘要：

  本发明公开了一种戊二酰亚胺类化合物与其应用。具体公开了式(VII-0)所示化合物及其药学上可接受的盐。

  公开号：

  WO2023036175A1

文献信息

• Enzyme Inhibitors
  申请人：Bavetsias Vassilios

  公开号：US20090247507A1

  公开（公告）日：2009-10-01

  Compounds of formula (I), are aurora kinase inhibitors: wherein X is —N—, —CH2—N—, —CH2—CH—, or —CH—; R1 is a radical of formula (IA) wherein Z is —CH2—, —NH—, -0-, —S(O)— —S—, —S(O)2 or a divalent monocyclic carbocyclic or heterocyclic radical having 3-7 ring atoms; Alk is an optionally substituted divalent C1-C6 alkylene radical; A is hydrogen or an optionally substituted monocyclic carbocyclic or heterocyclic ring having 5-7 ring atoms; r, s and t are independently 0 or 1, provided that when A is hydrogen then at least one of r and s is 1; R2 is halogen, —CN, —CF3, —OCH3, or cyclopropyl; and R3 is a radical of formula (IB) wherein Q is hydrogen or an optionally substituted phenyl or monocyclic heterocyclic ring with 5 or 6 ring atoms; Z&It;1> is —S—, —S(O)—, —S(O)2—, —O—, —SO2NH—, —NHSO2—, NHC(═O)NH, —NH(C═S)NH—, Or —N(R4)—wherein R4 is hydrogen, C1-C3 alkyl, cycloalkyl, or benzyl; and Alk&It;1> and Alk&It;2> are, independently, optionally substituted divalent C1-C3 alkylene radicals; and m, n and p are independently 0 or 1. Data supplied from the esp@cenet datatbase—Worldwide d77

  式(I)的化合物是极光激酶抑制剂：其中X是—N—、—CH2—N—、—CH2—CH—或—CH—；R1是式(IA)的基团，其中Z是—CH2—、—NH—、-O-、—S(O)—、—S—、—S(O)2或具有3-7个环原子的二价单环碳环或杂环基团；Alk是任选取代的二价C1-C6亚烷基基团；A是氢或任选取代的具有5-7个环原子的单环碳环或杂环环；r、s和t独立地为0或1，前提是当A为氢时，至少一个r和s为1；R2是卤素、—CN、—CF3、—OCH3或环丙基；R3是式(IB)的基团，其中Q是氢或任选取代的苯基或具有5或6个环原子的单环杂环环；Z<1>是—S—、—S(O)—、—S(O)2—、—O—、—SO2NH—、—NHSO2—、NHC(═O)NH、—NH(C═S)NH—或—N(R4)—，其中R4是氢、C1-C3烷基、环烷基或苄基；Alk<1>和Alk<2>独立地是任选取代的二价C1-C3亚烷基基团；m、n和p独立地为0或1。数据来自esp@cenet数据库—Worldwide d77。
• Imidazo[4,5-<i>b</i>]pyridine Derivatives As Inhibitors of Aurora Kinases: Lead Optimization Studies toward the Identification of an Orally Bioavailable Preclinical Development Candidate
  作者：Vassilios Bavetsias、Jonathan M. Large、Chongbo Sun、Nathalie Bouloc、Magda Kosmopoulou、Mizio Matteucci、Nicola E. Wilsher、Vanessa Martins、Jóhannes Reynisson、Butrus Atrash、Amir Faisal、Frederique Urban、Melanie Valenti、Alexis de Haven Brandon、Gary Box、Florence I. Raynaud、Paul Workman、Suzanne A. Eccles、Richard Bayliss、Julian Blagg、Spiros Linardopoulos、Edward McDonald

  DOI：10.1021/jm100262j

  日期：2010.7.22

  Lead optimization studies using 7 as the starting point led to a new class of imidazo[4,5-b]pyridine-based inhibitors of Aurora kinases that possessed the 1-benzylpiperazinyl motif at the 7-position, and displayed favorable in vitro properties. Cocrystallization of Aurora-A with 40c (CCT137444) provided a clear understanding into the interactions of this novel class of inhibitors with the Aurora kinases. Subsequent physicochemical property refinement by the incorporation of solubilizing groups led to the identification of 3-((4-(6-bromo-2-(4-(4-methylpiperazin-1-yl)phenyl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)methyl)-5-methylisoxazole (51, CCT137690) which is a potent inhibitor of Aurora kinases (Aurora-A IC(50) = 0.015 +/- 0.003 muM, Aurora-B IC(50) = 0.025 muM, Aurora-C IC(50) = 0.019 muM). Compound 51 is highly orally bioavailable, and in in vivo efficacy studies it inhibited the growth of SW620 colon carcinoma xenografts following oral administration with no observed toxicities as defined by body weight loss.
• [EN] GLUTARIMIDE COMPOUND AND USE THEREOF<br/>[FR] COMPOSÉ DE GLUTARIMIDE ET SON UTILISATION<br/>[ZH] 戊二酰亚胺类化合物与其应用
  申请人：[en]MEDSHINE DISCOVERY INC.;[zh]南京明德新药研发有限公司

  公开号：WO2023036175A1

  公开（公告）日：2023-03-16

  本发明公开了一种戊二酰亚胺类化合物与其应用。具体公开了式(VII-0)所示化合物及其药学上可接受的盐。